Evidence map›Paper›PMID 26567164›Full record

ArticleBMC infectious diseases2015

Monocyte unresponsiveness and impaired IL1β, TNFα and IL7 production are associated with a poor outcome in Malawian adults with pulmonary tuberculosis.

Catriona John Waitt, Peter Banda, Sarah Glennie, Beate Kampmann, S Bertel Squire, Munir Pirmohamed, Robert Simon Heyderman

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. TCA metabolism regulates DNA hypermethylation in LPS andProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Catriona John WaittMalawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, PO Box 30096, Chichiri, Blantyre, Malawi. cwaitt@liv.ac.uk.
Peter BandaDepartment of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi. npkbanda2000@yahoo.com.
Sarah GlennieMalawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, PO Box 30096, Chichiri, Blantyre, Malawi. sarahglennie1@gmail.com.
Beate KampmannImperial College London, London, UK. b.kampmann@imperial.ac.uk.
S Bertel SquireLiverpool School of Tropical Medicine, Liverpool, United Kingdom. s.b.squire@liv.ac.uk.
Munir PirmohamedDepartment of Molecular and Clinical Pharmacology, The University of Liverpool, Block A, The Waterhouse Buildings, 1-5 Brownlow Street, Liverpool, L69 3GL, United Kingdom. munirp@liv.ac.uk.
Robert Simon HeydermanMalawi-Liverpool-Wellcome Clinical Research Programme, University of Malawi College of Medicine, PO Box 30096, Chichiri, Blantyre, Malawi. livrsh@liv.ac.uk.
Liverpool School of Tropical Medicine · GBMalawi-Liverpool-Wellcome Trust Clinical Research Programme · MWImperial College London · GBUniversity of Liverpool · GBUniversity of Malawi · MW

Funding

Department of Health SRF-2009-02-07Medical Research Council G0700654Medical Research Council MC_EX_MR/K011944/1Medical Research Council MC_UP_A900_1122Wellcome Trust 076210/Z/04/ZWellcome Trust 100890
6 · The paper itself

Abstract

backgroundEarly death during TB treatment is associated with depressed TNFα response to antigenic stimulation and propensity to superadded bacterial infection. Hypothesising the role of monocyte unresponsiveness, we further compared the immunological profile between patients who died or suffered a life-threatening deterioration ('poor outcome') during the intensive phase of TB treatment with patients who had an uneventful clinical course ('good outcome') who had been recruited as part of a larger prospective cohort study of Malawian TB patients.

methodsUsing Luminex, IL1β, IL2, IL4, IL5, IL6, IL7, IL8, IL10, IL12, IL13, IL17, GCSF, GMCSF, MCP1, MIP1b, IFNγ and TNFα were measured in whole blood assay supernatants (stimulated with Mycobacterium tuberculosis H37Rv and LPS) and serum from 44 Malawian adult TB patients (22 of each outcome) immediately prior to commencing treatment, after 7 days and on day 56 of TB treatment. Monocyte surface expression of CD14, CD16, TLR2, TLR4, CD86 and HLADR, and intracellular TNFα were measured by flow cytometry as was intracellular TNFα response to purified TLR ligands.

resultsLower TB antigen-induced IL1β (p = 0.006), TNFα (p = 0.02) and IL7 (p = 0.009) were produced in the poor outcome group. TNFα was produced by 'classical' CD14(hi)CD16(lo) monocytes, with no correlation between this response and expression of monocyte surface markers. Response to TB antigens correlated with responses to the purified TLR 2, 3 and 4 ligands.

conclusionsDysregulated monocyte cytokine production was identified in TB patients with poor outcome. Lower TNFα responses to H37Rv paralleled lower responses to a panel of TLR ligands, suggesting an underlying perturbation in common TLR signalling pathways. Future work should explore the role of TLR polymorphisms in immune response and clinical outcome in TB patients.

Indexed as

AdolescentAdultAgedCytokinesFemaleHumansInterleukin-1betaInterleukin-7LipopolysaccharidesMalawiMaleMiddle AgedMonocytesMycobacterium tuberculosisProspective StudiesTreatment OutcomeCytokinesIL7 protein, humanInterleukin-1betaInterleukin-7LipopolysaccharidesTNF protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID26567164
PMCPMC4643523
OpenAlexW2178574468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.